 |
Biotechnology / BiopharmaceuticalsPlease see below a list of all our SVLSF investments by sector.To go to individual portfolio companies websites please click on company logo. 
Achillion: USFirst investment: 2000 - Start Up Dedicated to bringing important new treatments to patients with infectious disease. Anti-infective drug development. 
Aderis Pharmaceuticals: USFirst investment: 2001 - Expansion - Exited Cardiovascular, renal and neurological disease focused therapeutics focused upon making a significant difference to people living with cardiovascular, renal and neurological diseases. 
Affibody: SwedenFirst investment: 2001 - Early Stage Molecular imaging and targets therapeutics. 
Affinium Pharmaceuticals : Canada First investment: 2007 - Early Stage Affinium is a pharmaceutical company focused on the clinical development of antibacterials. 
Alantos
Pharmaceuticals: USFirst investment: 2003 - Early Stage Combinatorial chemistry focused upon lead discovery and optimization (Previously known as Therascope). 
Alba Therapeutics: USFirst investment: 2005 - Early Stage For the treatment of inflammatory and immune mediated diseases. Alinea: US First investment: 2005 - Expansion Alinea is a spinout that will develop a PTP1b inhibitor for insulin resistance. 
Allos Therapeutics: US First investment: 1998 - Early Stage - Exited Developing and commercializing innovative small molecule therapeutics for the treatment of cancer. 
Archemix: USFirst investment: 2002 - Early Stage Develops aptamers as a new class of direct therapeutics for the prevention and treatment of chronic and acute disease. 
Auxilium Pharmaceuticals: USFirst investment: 2001 - Early Stage Male Hormone Replacement Therapy. 
Avera Pharmaceuticals: USFirst investment: 2004 - Early Stage Development and commercialization of novel pharmaceutical compounds for treatment of neurologic and psychiatric disorders. 
Axys Pharmaceuticals: USFirst investment: 1994 - Early Stage - Exited Protease-inhibitor based products for cancer & inflammatory diseases. 
Cellzome: GermanyFirst investment: 2001 - Start Up Proteomics technology for target and lead identification, and a drug discovery program in Alzheimer's Disease.  Cerebrus:
UKFirst investment: 1995 - Start Up - Exited CNS drug discovery (Acquired by Nigra, which was then bought by Vernalis) 
Cognis: LuxembourgFirst investment: 2001 - Buy Out Speciality chemicals. Products and solutions for personal care, home care and modern nutrition.  Cytomed:
USFirst investment: 1997 - Early Stage - Exited Leukotriene inhibitors for asthma (Acquired by LeukoSite and then by Millenium formerly known as Cytomed share). 
Dynogen Pharmaceuticals: USFirst investment: 2004 - Early Stage Genito-urinary and gastro-intestinal disorders using neuroscience-based pharmaceutical drugs. 
Eyetech Pharmaceuticals: USFirst investment: 2000 - Early Stage - Exited Bought by OSI Pharmaceuticals after our exit. Opthalmolological drug development. 
ESBATech: SwitzerlandFirst investment: 2006 - Early Stage ESBATech is a preclinical stage drug discovery company exploiting a novel platform for antibody fragment discovery. 
EUSA Pharma : US First investment: 2007 - Early Stage A specialty pharmaceutical company focused on developing and marketing innovative products for the worldwide hospital market.  Fundamental Applied Biology, Inc.: US First investment: 2006 - Early Stage Fundamental Applied Biology (FAB), Inc. mission is enable the production of low-cost, high quality rapidly developed products and technology for protein pharmaceuticals and innovative vaccines. 
Geltex Pharmaceuticals: USFirst investment: 1995 - Early Stage - Exited Further investment: 1998 - Expansion - Exited Development of novel non-absorbed pharmaceuticals. Acquired by Genzyme Corporation after our exit. 
GlycoFi: USFirst investment: 2002 - Start Up - Exited Production and engineering of therapeutics proteins. 
Incyte Pharmaceuticals: UKFirst investment: 1996 - Start Up - Exited Functional genomics (Acquired by Incyte). 
Ingenium: GermanyFirst investment: 2000 - Early Stage Functional genomics and drug development. 
Intranasal Therapeutics: USFirst investment: 2006 - Early Stage Intranasal Therapeutics, Inc. ("ITI") is a specialty pharmaceutical company focused on developing innovative, nasally delivered pharmaceutical products with a particular focus on drugs treating pain and CNS-related disorders. 
Kinetix Pharmaceuticals: USFirst investment: 1999 - Start Up - Exited Kinase targeted drug discovery (Acquired by Amgen). 
KuDOS Pharmaceuticals: UKFirst investment: 1999 - Start Up - Exited Oncology drug development.
Leukosite: USFirst investment: 1994 - Start Up - Exited Treatment of Inflammatory diseases and cancer (Acquired by Millenium).  Lorantis:
UKFirst investment SVLSF II: 2000 - Start Up First investment SVLSF III: 2003 - Early Stage Immunology based drugs. 
Lux Bioscience: USFirst investment: 2006 - Seed Opthalmic drugs 
Metris Therapeutics: UKFirst investment SVLSF I: 1998 - Start Up First investment SVLSF II: 2000 - Start Up Treatment of gynaecological disorders. 
Micromet: GermanyFirst investment: 1998 - Start Up Drug discovery using novel protein drugs 
Mpex Pharmaceuticals: USFirst investment: 2005 - Early Stage Development of new anti-bacterial drugs that meet the growing clinical need created by multi-drug resistant bacterial pathogens. 
Neurotech: USFirst investment: 2006 - Early Stage Neurotech is a biotechnology company dedicated to the development of sight-saving therapeutics for chronic retinal diseases. 
Orchid Chemicals and Pharmaceuticals: IndiaPrivate investment in Public Equity First investment: 1999 - Expansion - Exited Manufacture of bulk generic pharmaceuticals. 
Oxagen: UKFirst investment: 2000 - Expansion Clinical genomics. 
PowderMed: UKFirst investment: 2004 - Early Stage - Exited Development of therapeutic DNA vaccines in the areas of chronic viral diseases and cancer. 
Quantum Dot: USFirst investment: 2000 - Early Stage - Exited Nanocrystal biological reagents. 
Rinat Neuroscience: USFirst investment: 2003 - Early Stage - Exited Developing proteins for the treatment of diseases and disorders of the nervous system. 
Sapphire Therapeutics: USFirst investment: 2004 - Early Stage Developing compounds for treatment of oncologic and metabolic diseases. (Formerly know as Rejuvenon). 
Shire Pharmaceuticals: USFirst investment: 1994 - Early Stage - Exited Osteoporosis and Alzheimer's disease. 
Solexa: UKFirst investment: 2001 - Start Up Ultra high throughput DNA sequencing. 
Strides Arcolab: IndiaFirst investment: 1997 - Expansion - Exited Manufacturer of generic pharmaceuticals. 
Third Wave Technologies: USFirst investment: 1999 - Expansion - Exited Products for analysing genetic variations 
Triangle Pharmaceuticals: USFirst investment: 1995 - Start Up - Exited Antiviral and anticancer drug development (Acquired by Gilead). 
Trine Pharmaceuticals: USFirst investment: 2001 - Expansion Anti-infective drug discovery. (Formerly known as Essential Therapeutics 'ETRX').
Vanguard Medica (Vernalis): UKFirst investment: 1995 - Early Stage - Exited Antiviral and anticancer drug development. (Acquired by Vernalis). 
Versicor: USFirst investment: 1999 - Expansion - Exited Drug development for infectious diseases (Changed name to Vicurion Pharmaceuticals in 2003) 
|
